Cardiotoxicity Clinical Trial
— PROTHYMOfficial title:
PROTHYM - Phase II Non-randomized Study on Proton Radiotherapy Of Thymic Malignancies
This is a multicentre non-randomized phase II study of proton beam radiotherapy in patients with thymic epithelial tumours (i.e. thymoma and thymic carcinoma) in the post-operative setting or in inoperable patients with localized disease. Patients not willing or for any reason unsuitable to undergo proton treatment will be asked to participate in a follow-up assessment after the regular photon treatment in the same manner as the included patients. Primary endpoints are:Toxicity (e.g. cardiac and pulmonary toxicity) and Local control at 5 year Secondary endpoints: PFS, Overall survival, Quality of life, measured by EORTC QLQ 30 + LC 13 and relapse pattern
Status | Recruiting |
Enrollment | 40 |
Est. completion date | April 1, 2029 |
Est. primary completion date | April 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histological or cytological diagnosis of thymoma or thymic carcinoma. - With radical surgery: stage III and IVa and selected stage II with type B2, B3 and thymic carcinoma according to local routine. With non-radical surgery (R1 or R2) or inoperable patient/ patient refusing surgery: stage I - IVa, any histology - PS WHO 0 - 2. - FEV1 > 1L or >40 % of predicted and CO diffusion capacity > 40% of predicted (postoperative measures) - Age >18 years, no upper age limit. - Written informed consent from patients. Exclusion Criteria: - Masaoka-Koga stage IVb (distant metastases). - Pregnancy. - Serious concomitant systemic disorder incompatible with the study. - Tumour motion > 0.5 cm on two repeated 4DCT |
Country | Name | City | State |
---|---|---|---|
Sweden | Department of Oncology, Sahlgrenska University Hospital | Gothenburg | Västra Götaland |
Sweden | Department of Oncology, Karolinska University Hospital | Stockholm | Stockholm County |
Sweden | Department of Oncology, Norrlands Universitetssjukhus | Umeå | Norrland |
Lead Sponsor | Collaborator |
---|---|
Ass. Prof. Jan Nyman |
Sweden,
Björk-Eriksson T, Bjelkengren G, Glimelius B. The potentials of proton beam radiation therapy in malignant lymphoma, thymoma and sarcoma. Acta Oncol. 2005;44(8):913-7. Review. — View Citation
Chang JY, Li H, Zhu XR, Liao Z, Zhao L, Liu A, Li Y, Sahoo N, Poenisch F, Gomez DR, Wu R, Gillin M, Zhang X. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):809-18. d — View Citation
Gomez D, Komaki R. Technical advances of radiation therapy for thymic malignancies. J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S336-43. doi: 10.1097/JTO.0b013e3181f20ea2. Review. — View Citation
Vogel J, Berman AT, Lin L, Pechet TT, Levin WP, Gabriel P, Khella SL, Singhal S, Kucharczuk JK, Simone CB 2nd. Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma: Early response and tox — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cardiotoxicity and pulmonary toxicity of therapy | Proportion of patients with cardiac and pulmonary toxicity measured by CTCAE 4.0 > Grade 2 | At 60 months from treatment | |
Primary | Local tumor control | Freedom from tumor progression (CR,PR or SD) mesured by CT-scan | At 60 months from treatment | |
Secondary | Quality of life questionnaire EORTC QLQ 30 (European Organisation for Research and Treatment of Cancer) | Scale from 1-100 for 30 items, higher score indicates a better situation. | At 60 months from treatment | |
Secondary | Quality of life questionnaire LC13 (Lung cancer specific module of EORTC) | Scale from 1-100 for 13 items and higher score indicates worse symptoms. | At 60 months from treatment | |
Secondary | Survival | Overall survival | From treatment and for 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05271162 -
Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines
|
Phase 3 | |
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Recruiting |
NCT04092309 -
Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation
|
N/A | |
Recruiting |
NCT04790266 -
Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients
|
||
Enrolling by invitation |
NCT04305613 -
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
|
||
Not yet recruiting |
NCT05040867 -
Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients
|
N/A | |
Recruiting |
NCT05851053 -
Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
|
||
Recruiting |
NCT05992337 -
New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
|
||
Enrolling by invitation |
NCT04877899 -
Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol
|
||
Recruiting |
NCT05096338 -
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
|
||
Recruiting |
NCT05078190 -
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
|
||
Recruiting |
NCT04632407 -
Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study?
|
N/A | |
Completed |
NCT00543062 -
Staccato Prochlorperazine Thorough QT/QTc
|
Phase 1 | |
Recruiting |
NCT05159479 -
Defining Robust Predictors of Chemotherapy Related Cardiotoxicity
|
||
Not yet recruiting |
NCT06005259 -
Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)
|
Phase 4 | |
Recruiting |
NCT05406635 -
Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer
|
N/A | |
Recruiting |
NCT04047901 -
Effect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer Treatment
|
N/A | |
Terminated |
NCT03038997 -
Early Detection of Cardiac Toxicity in Childhood Cancer Survivors
|
||
Completed |
NCT01246778 -
Sunitinib and Atrial Trabeculae Contractility
|
N/A |